Login / Signup

Telavancin pharmacokinetics in patients with chronic kidney disease receiving haemodialysis.

Katherine N GharibianSusan J LewisMichael HeungJonathan H SegalNoha N SalamaBruce A Mueller
Published in: The Journal of antimicrobial chemotherapy (2021)
Haemodialysis with high-permeability haemodialysers removes telavancin considerably (∼⅓ of body load). Telavancin 5 mg/kg every 48 h post-haemodialysis dosing is recommended, but dose adjustments may be warranted if haemodialysis starts within 3 h of telavancin administration.
Keyphrases
  • end stage renal disease
  • peritoneal dialysis
  • chronic kidney disease
  • endothelial cells